Loading...
Loading...
BioTime, Inc.
BTX today announced that it has obtained an
exclusive license from The Wistar Institute in Philadelphia, PA for technology
related to a gene designated as SP100. Wistar Institute researchers have
demonstrated pivotal roles for this gene in both cancer and stem cell biology.
Scientists at BioTime's subsidiaries OncoCyte Corporation and ReCyte
Therapeutics plan to apply this technology in the development of innovative
medical products for cancer and vascular diseases. In conjunction with the
license agreement, BioTime has agreed to fund research at The Wistar Institute
to advance the technology, and BioTime will receive certain rights to
negotiate additional licenses for any technologies invented as a result of the
research.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in